^
    Back
    Association details:
    Biomarker:HR positive
    Cancer:Hormone Receptor Positive Breast Cancer
    Drug:exemestane (Aromatase inhibitor)
    Drug Class:HDAC inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Prospective Study of UDP-gluconoryltransferase 2B17 Genotype as a Predictive Marker of Exemestane PK and PD

    Excerpt:
    ...- Histologically-proven hormone-receptor positive metastatic breast carcinoma...
    Trial ID:
    NCT01655004
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

    Excerpt:
    ...- Patients must have hormone receptor positive tumors; if there is more than one breast tumor, each tumor must be hormone receptor positive; hormone receptors must be determined using immunohistochemistry; estrogen receptor (ER) and/or progesterone receptor (PgR) must be greater than or equal to 10% of the tumor cells positive by immunohistochemical evaluation; biochemical determination alone is...
    Trial ID:
    SOFT
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    Phase II study of Exemestane dose intensification (150 mg daily) in postmenopausal patients with advanced breast cancer progressing under standard dose Exe (25 mg daily) given as adjuvant or palliative therapy

    Excerpt:
    ...Steroid hormone receptor positive tumours (ER and/or PgR), determined by immunohistochemistry (IHC). ...
    Trial ID:
    2008-004169-25
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Exp Ther Med
    Title:

    Comparison of a histone deacetylase inhibitor plus exemestane with exemestane alone in hormone receptor-positive advanced breast cancer that progressed on prior endocrine therapy: A meta-analysis

    Published date:
    07/18/2022
    Excerpt:
    Herein, we conducted a meta-analysis to evaluate the efficacy and safety of an HDAC inhibitor plus exemestane vs. exemestane alone in this setting. Our meta-analysis demonstrated that the combination group exhibited significantly prolonged progression-free survival (PFS) [hazard ratio (HR)=0.776, 95% confidence interval (CI)=0.675-0.892, P=0.000] and an improved objective response rate (ORR) (RR=1.612, 95% CI=1.085-2.396, P=0.018) compared to those treated with exemestane alone....In conclusion, the addition of an HDAC inhibitor to exemestane significantly improves PFS over exemestane alone in hormone receptor‑positive ABC patients...
    DOI:
    10.3892/etm.2022.11512